Cetuximab with irinotecan/FA/5-FU as first-line treatment in advanced gastro esophageal cancer: A prospective multi-center and biomarker-oriented phase II study
M Moehler, A Müller, T Trarbach, T Seufferlein, S Kubicka, M Geissler, F Lordick, S Daum, S Kanzler, P Galle · Zeitschrift für Gastroenterologie · 2010 · Heft 08
Bibliografische Angaben
Zusammenfassung
To evaluate the tolerability and efficacy of cetuximab combined with irinotecan/folinic acid/5-fluorouracil (IF) as first-line treatment in patients with advanced gastric cancer and cancer of the gastroesophageal junction. Patients and methods: Patients received weekly cetuximab (400mg/m2 day-1, subsequently 250mg/m2) plus irinotecan (80mg/m2) and a 24-hour continuous infusion of sodium folinic acid (200mg/m2) and 5-fluorouracil (1500mg/m2) on days 1, 8, 15, 22, 29 and 36 of a 50-day cycle, until tumor progression. In parallel tumors were assessed for KRAS, BRAF, and PIK3CA mutations by PCR and for EGFR, VEGF-C,…
